Meta-Analysis: Psilocybin Outperforms Traditional Therapies for Depression Relief
- A study published in the Journal of Psychopharmacology examined the effectiveness of psilocybin in treating depression.
- Researchers conducted a meta-analysis using data from Medline and the Cochrane Library databases to evaluate the therapeutic impact of psilocybin on depression.
- Results showed a large reduction in depressive symptoms in patients receiving psilocybin alongside therapy compared to baseline measurements and placebo.
- The study concluded that psilocybin is more effective in treating depression compared to established psychotherapy alone and suggests the need for further research with larger sample sizes and longer timeframes.
Dried psilocybin mushrooms.
Published in the Journal of Psychopharmacology, the study was conducted by researchers from Alborz University of Medical Sciences, Tehran University of Medical Sciences, and Shahid Beheshti University of Medical Sciences, all in Iran.
“Due to the unsatisfactory therapeutic effects of current antidepressants, research has been launched into alternative treatment approaches, such as the administration of psychedelics”, states the study. “Psilocybin, a classic hallucinogen, has been shown to exert considerable positive influence on depression symptoms through its serotonergic and glutamatergic effects. This systematic review and meta-analysis aimed to evaluate the effectiveness of psilocybin in treating depression.” For the meta-analysis, a comprehensive search of Medline (via PubMed) and the Cochrane Library databases was conducted to identify relevant studies. Inclusion criteria were applied to select studies that investigated the therapeutic impact of psilocybin on depression. A mixed-effects multi-level model was used to estimate the overall effect size. Effectiveness over time was also investigated as a secondary analysis.
“The results of the primary analysis revealed a large and clinically observable reduction (SMC: -1.24, 95%CI: -1.83 to -0.65, I2level2 = 11.39%, I2level3 = 77.67%) of depressive symptomatology in patients receiving psilocybin in addition to supportive therapy compared to baseline measurements”, states the study’s researchers. “The decrease was also marked when compared to placebo (p-value = 0.032). The results remained significant even when a secondary analysis assessed the effect in various time intervals since the administration of psilocybin.”
Researchers conclude:
This systematic review and meta-analysis substantiate the claim that psilocybin is superior in treating depression compared to established psychotherapy alone used for treating depression. This finding warrants further studies with larger sample sizes and across a longer timeframe.